Naloxone Recalled by Manufacturer, FDA Announces

June 13, 2018

The U.S. Food and Drug Administration (FDA) announced June 4 that Hospira issued a voluntary nationwide recall for two lots of naloxone, the drug most commonly used to reverse opioid overdose.

Hospira issued the recall due to “the potential presence of embedded and loose particulate matter on the syringe plunger,” according to the FDA press release.

According to the FDA, patients who take defective naloxone could experience the following adverse reactions:


In April, the U.S. Surgeon General released an advisory urging more Americans to personally carry naloxone.

Read the FDA press release.